Publications
5803 Results
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3145 poster
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405
- Journal / Conference
- AACR 2025; Journal: Cancer Research, Cancer Res (2025) 85 (8_Supplement_1): 2787
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Abstract 2787: Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e20_70093
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB-AVD VERSUS Bv-AVD IN PATIENTS ENROLLED ON SWOG S1826
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e127_70093
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
HEALTH-RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e368_70093
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
THE ASSOCIATION OF SOCIAL DISADVANTAGE WITH OUTCOMES IN PATIENTS WITH ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA ENROLLED IN THE PHASE 3 INTERGROUP TRIAL S1826
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e233_70093
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1608
S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)
- Journal / Conference
- Euro Hem Assoc mtg June 2025, #S118
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- C10403
LONG-TERM FOLLOW-UP OF AN INTENSIVE PEDIATRIC REGMEN FOR ADOLESCENTS/YOUNG ADULTS (AYA) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): 10-YEAR SURVIVAL FOLLOWING CALGB 10403 (ALLIANCE)
- Journal / Conference
- Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2900. Online ahead of print.
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID41378983
- Study Number(s)
- S1609
Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)
- Journal / Conference
- J Natl Cancer Inst. 2025 Dec 1;117(12):2643-2652. doi: 10.1093/jnci/djaf281.NIHMS2114152
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID40996326
- PMC
- PMC12629277
- Study Number(s)
- CTSU/C80702
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)
- Journal / Conference
- Eur Urol Focus. 2025 Dec 6:S2405-4569(25)00343-8. doi: 10.1016/j.euf.2025.11.011. Online ahead of print.
- Year
- 2025
- Research Committee(s)
- Genitourinary
- PMID
- PMID41354605
- Study Number(s)
- S2210